The historical rank and industry rank for Clarus Therapeutics Holdings's EV-to-FCF or its related term are showing as below:
CRXWQ'
s EV-to-FCF Range Over the Past 10 Years
Min: -6.87 Med: -0.64 Max: -0.38
Current: -0.38
During the past 2 years, the highest EV-to-FCF of Clarus Therapeutics Holdings was -0.38. The lowest was -6.87. And the median was -0.64.
CRXWQ's EV-to-FCF is not ranked
in the Drug Manufacturers industry.
Industry Median: 22.13
vs CRXWQ: -0.38
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Clarus Therapeutics Holdings's EV-to-FCF
For the Drug Manufacturers - Specialty & Generic subindustry, Clarus Therapeutics Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clarus Therapeutics Holdings's EV-to-FCF Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Clarus Therapeutics Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Clarus Therapeutics Holdings's EV-to-FCF falls into.
Clarus Therapeutics Holdings EV-to-FCF Calculation
Clarus Therapeutics Holdings's current Enterprise Value is $0.00 Mil.
Clarus Therapeutics Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-56.64 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clarus Therapeutics Holdings (OTCPK:CRXWQ) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Clarus Therapeutics Holdings's PE Ratio (TTM) for today is calculated as:
Clarus Therapeutics Holdings's share price for today is $0.0003.
Clarus Therapeutics Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Clarus Therapeutics Holdings EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Clarus Therapeutics Holdings's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Clarus Therapeutics Holdings Inc is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company is focused on focused on the commercialization of JATENZO (testosterone undecanoate), the first and only oral testosterone replacement, or testosterone replacement therapy, and JATENZO is the sole source of company's revenue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CRXWQ has been successfully added to your